Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Celldex Therapeutics, Inc. (CLDX), Cytokinetics, Inc. (CYTK): Are These Top Biotech Performers Still Worth Buying?

Page 1 of 2

Only a handful of stocks have gained 200% in 2013, and five of those stocks are in the biotechnology industry. Perhaps you already own one, or maybe a couple of these stocks? Maybe you are considering an investment? Well, let’s take a look at the top 5 biotech performers, and determine whether larger gains will be realized.

No. 5: Cancer Stock on the Move

Celldex Therapeutics, Inc. (NASDAQ:CLDX)
Celldex Therapeutics, Inc. (NASDAQ:CLDX) has seen a 200% gain this year after 33% of patients being treated with its breast cancer drug CDX-011, showed a response, compared to zero percent in the chemotherapy arm of the trial.

If analyst upgrades and initiations of coverage count as catalysts, then Celldex Therapeutics, Inc. (NASDAQ:CLDX) has had a busy year. But in reality, the majority of the company’s gains have occurred because expectations for CDX-011 were unusually low prior to its positive data.

Now, the company awaits results from a Phase 3 trial for its glioblastoma (brain cancer) product, rindopepimut, which I estimate has peak annual sales of $600 million.

Combined, Celldex Therapeutics, Inc. (NASDAQ:CLDX) has two late-stage successful products with peak revenue potential of $1.3 billion, and a solid pipeline. As a result, I think Celldex Therapeutics, Inc. (NASDAQ:CLDX), with a market cap of $1.6 billion, is still extremely attractive. Although, I would expect a much slower pace of gains moving forward.

No. 4: Success After Failure

Keryx Biopharmaceuticals (NASDAQ:KERX) failed to meet key endpoints in a 2012 Phase 3 study for its colorectal cancer drug perifosine, but has since rallied higher with new data in 2013. During this year, Keryx Biopharmaceuticals (NASDAQ:KERX) has traded higher by 208%, as its kidney disease drug Zerenex met its late-stage trial goal of reducing phosphate levels in blood.

According to analysts, the company’s drug, Zerenex, could generate $800 million in peak global sales and $300 million in U.S. sales.

However, this is not a company that excites me. I have watched since Zerenex’s data was announced earlier this year, and peak sales estimates have risen from $150 million, to $200 million, and now $300 million in the U.S. Unfortunately, for the company, nothing has changed with advanced kidney disease demand. Hence, I don’t think Zerenex will meet the newly inflated peak sales expectations, and with a market cap of $660 million, I think the company is fairly valued.

No. 3: A Cardiovascular Stock to Watch

The majority of Cytokinetics, Inc. (NASDAQ:CYTK)’ 226% gains in 2013 have been created since June. First, its strategic collaboration with Amgen was expanded to include Japan for the commercialization of small-molecule therapeutics for the treatment of heart failure. Then the company was selected to present results from its Phase 2 heart disease study at a prominent European event. To many, this signaled that its experimental drug for acute heart failure is working.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!